Carol Ann Huff

Building on the first patient case, Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how recently presented MajesTEC-9 data may influence treatment selection for patients with relapsed/refractory multiple myeloma (RRMM) who experience an early relapse following frontline therapy. Dr. Mewawalla explains how remission duration, disease biology, patient age, and anti-CD38 treatment history factor into her interpretation of the available evidence and subsequent treatment recommendations.

Using a case-based scenario, Dr. Binod Dhakal and Dr. Carol Ann Huff explore treatment decision-making for a fit patient with relapsed/refractory multiple myeloma (RRMM) experiencing first relapse approximately 30 months after autologous stem cell transplantation. The discussion focuses on a patient with prior anti-CD38 exposure but uncertain anti-CD38 refractoriness, highlighting the importance of accurately characterizing prior treatment response before selecting subsequent therapy.

Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss the growing number of BCMA-directed bispecific antibody options available for patients with relapsed/refractory multiple myeloma (RRMM) and the practical considerations that influence treatment selection.